Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series Ltd: World’s leading Event Organizer
As per available reports Antiviral Therapy involves 1 relevant journals, 1 Conference and 61 National symposiums are presently dedicated exclusively to Antiviral Therapy and about 198 open access articles and 745 Conference Proceedings are being published on Antiviral Therapy.
The field of antiviral therapy is expanding at an unprecedented rate. Antiviral and Therapeutics emerging viruses (avian and swine influenza strains, SARS, etc.), and viruses relevant to potential bioterrorism (Ebola, smallpox, etc.). Antiviral drugs are prescription medicines (pills, liquid, an inhaled powder, or an intravenous solution) that fight against the flu in your body. A novel antiviral approach that is effective against a very broad spectrum of viruses, nontoxic in vitro and in vivo, and potentially suitable for either prophylactic or therapeutic administration.
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
Scope and Importance:
The pharmacology and use of antiviral drugs has been introduced for an overall reassessment of antiviral therapy, considering older approaches, such as post-exposure immunization, along with the newer chemotherapy, is lacking. Antiviral Therapy Conference highlight the assessments of drug and vaccine safety, use of antiviral drugs, antibodies and host-response modifiers, evolution of drug- or vaccine-resistant viruses and the development of effective countermeasures, identification and validation of new drug targets and many more.
Antiviral agents which are useful to restrict, a number of clinical situations. Furthermore, most antiviral drugs do not selectively inhibit virus replication without simultaneously injuring the host cell, and are therefore accompanied by serious side effects. Thus, possible beneficial effects of antiviral drugs must be balanced against potential immune-suppressive and other undesirable side effects. Nevertheless, the physician, faced with a seriously ill patient or concerned about the individual and economic consequences of an incipient epidemic of viral disease, is under considerable pressure by the patient, by the public or by his colleagues, to apply antiviral therapy. Although the pharmacology and use of antiviral drugs has been introduced for an overall reassessment of antiviral therapy, considering older approaches, such as post-exposure immunization, along with the newer chemotherapy, is lacking. Virus structure: Viruses contain a single type of nucleic acid, either ribonucleic acid (RNA) or deoxyribonucleic acid (DNA). The viral core, composed of the nucleic acid and nucleoproteins is protected by an outer protein coat (the capsid). Jr addition, some virus. arc surrounded by a lipoprotein envelope. Virus cell interactions: Virus are obligate intracellular parasites. The field of antiviral therapy is expanding at an unprecedented rate. The tremendous expansion in drug screening and rational drug design brought about by the HIV pandemic, together with gathering interest in new viral targets' such as the hepatitis and papillomaviruses, means that more antiviral agents than ever are reaching clinical trials.
Market revenue is forecast to increase at a five-year compound annual growth rate (CAGR) of 8% from 2013 to 2018, totaling nearly $6 billion in 2018. The market is broken down into vaccines, therapeutics, and diagnostic products. The therapeutics segment has the second-largest share of the market with $2.1 billion in 2009. But that segment is expected to decrease at a CAGR of -2.4%, falling to $1.9 billion in 2014. As many as 500,000 people die of influenza annually and with the threat of a pandemic, government agencies and disease-prevention organizations are devoted to gaining control of the situation.
International symposium and workshops
29th International Conference on Antiviral Research (ICAR), April 17-21, 2016, USA.
British Infection Association's 9th HIV Dilemmas Meeting, January 29 2016, UK.
5th Eastern Europe and Central Asia AIDS Conference, March 23-25, 2016, Russia.
List of Best International Conferences:
2nd Flu Conference
November 17-19, 2016 San Francisco, USA.
2nd Infectious Diseases Congress
August 25-27, 2016 Philadelphia, USA.
2nd Parasitology Conferences
August 01-03, 2016 Manchester, UK.
2nd Influenza Conferences
September 12-14, 2016 Berlin, Germany.
Children Vaccines Congress
October 10-12, 2016 Kuala Lumpur, Malaysia.
4th Immunology Conference
October 24-26, 2016, Chicago, USA.
European Infectious Diseases Conference
August 1-3, 2016 Frankfurt, Germany.
Relevant Society and Associations
This page will be updated regularly.
This page was last updated on 11th Sep, 2015
1-702-508-5200 Ext:8031, 8041
1-702-508-5200 Ext:8045, 8047
Immunology & Microbiology Conferences
Nursing and Healthcare Conferences
Clinical and Biochemistry Conferences
1-702-508-5200 Ext:8031, 8037
Material Science Conferences
Genetics & Mol Biology Conferences
Media Partners | Advertising